Non-Narcotic Pain Control After ACL Reconstruction
1 other identifier
interventional
30
1 country
3
Brief Summary
This is a double-blind randomized controlled trial of standard of care therapy, either oral ketorolac (experimental group) or oral oxycodone (control group) to demonstrate efficacy in reducing the percentage of narcotic doses taken and documenting the number of patients with no exposure to any narcotics (take zero oxycodone) after undergoing primary knee ACL reconstruction outpatient surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Jul 2025
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 7, 2025
CompletedFirst Posted
Study publicly available on registry
May 15, 2025
CompletedStudy Start
First participant enrolled
July 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 12, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 15, 2027
ExpectedAugust 24, 2026
June 1, 2026
11 months
March 7, 2025
August 20, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Primary outcome
How many narcotic pills were consumed
30 days
Study Arms (2)
Oxycodone- Narcotic
ACTIVE COMPARATORArm 1
Ketorolac
PLACEBO COMPARATORArm 2
Interventions
Patients will be randomized to either Ketorolac or Oxycodone
• Cohort Group 1 (Experimental): ketorolac 10mg with rescue medication oxycodone 5mg All patients will be given acetaminophen
Eligibility Criteria
You may qualify if:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 15-55 years
- Primary Autograft ACL surgery
- Ability to take oral medication and willingness to patriciate in a virtual 1 week follow-up pill count visit
You may not qualify if:
- \. Any extensor mechanism dislocation or disruption 2. Multi-ligament injury that requires repair 3. Treatment with another investigational drug or other intervention concurrently or previously that would interfere with postoperative pain control 4. Psychiatric illness that impedes evaluation of pain and/or narcotics use 5. History of Chronic Kidney Disease 6. History of inflammatory arthritis, diabetes, or autoimmune disease 7. History of GI bleed or documented GI ulcer (diagnosed by endoscopy) 8. Allograft or revision of ACLR 9. Contraindications to ketorolac or opioids
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
Cleveland Clinic Coral Springs
Coral Springs, Florida, 33067, United States
Cleveland clinic sports medicine
Garfield, Ohio, 44125, United States
Cleveland Clinic
Strongsville, Ohio, 44136, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Kurt P Spindler, MD
The Cleveland Clinic
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lead Principal Investigator
Study Record Dates
First Submitted
March 7, 2025
First Posted
May 15, 2025
Study Start
July 15, 2025
Primary Completion
June 12, 2026
Study Completion (Estimated)
June 15, 2027
Last Updated
August 24, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- They will be available from the start date to the end date
Only IPD will be used in the results publications